Vaginal Misoprostol In Medical Treatment of First Trimester Missed Miscarriage
NCT ID: NCT05094375
Last Updated: 2021-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2021-11-01
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vaginal Misoprostol 600 mcg
All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.
* Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).
* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.
* A specimen bottle to collect the POC if passed out.
* Two pairs of disposable gloves.
* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Vaginal Misoprostol 600 mcg
All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.
* Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).
* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.
* A specimen bottle to collect the POC if passed out.
* Two pairs of disposable gloves.
* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Vaginal Misoprostol 800 mcg
All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.
* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).
* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.
* A specimen bottle to collect the POC if passed out.
* Two pairs of disposable gloves.
* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Vaginal Misoprostol 800 mcg
All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.
* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).
* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.
* A specimen bottle to collect the POC if passed out.
* Two pairs of disposable gloves.
* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vaginal Misoprostol 600 mcg
All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.
* Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).
* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.
* A specimen bottle to collect the POC if passed out.
* Two pairs of disposable gloves.
* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Vaginal Misoprostol 800 mcg
All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.
* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).
* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.
* A specimen bottle to collect the POC if passed out.
* Two pairs of disposable gloves.
* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Less than 12 weeks of gestation.
* Pregnancy is confirmed by pregnancy test or ultrasound scan.
* missed abortion
* Normal general and gynecological examination.
Exclusion Criteria
* Suspected sepsis with temperature 38 °C.
* Concurrent medical illness e.g. hematological, cardiovascular, thromboembolism,
* respiratory , recent liver disease, or pruritus of pregnancy.
* Presence of intrauterine contraceptive device (IUCD).
* Suspect or proven ectopic pregnancy.
* Failed medical or surgical evacuation before the presentation.
* Known allergy to misoprostol.
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
hany farouk
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
hany farouk
Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aswan University Hospital
Aswān, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
aswu/354/10/19
Identifier Type: -
Identifier Source: org_study_id